

10 September 2026

Biologics Dermatology

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira	29
• Adalimumab Biosimilar	300
• Apremilast – Otezla	<5
• Apremilast generic	<5
• Bimekizumab	18
• Brodalumab	0
• Certolizumab	7
• Deucravacitinib	0
• Dimethyl fumarate	0
• Etanercept – Enbrel	<5
• Etanercept Biosimilar	5
• Guselkumab	96
• Infliximab – Remicade	<5
• Infliximab Biosimilar	12
• Ixekizumab	64
• Risankizumab	<5
• Secukinumab	68
• Tildrakizumab	<5
• Ustekinumab – Stelara	<5
• Ustekinumab Biosimilar	105
• Omalizumab	46
• Spesolimab	0

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

• Adalimumab – Humira	10
• Adalimumab Biosimilar	47
• Bimekizumab	<5
• Certolizumab	0
• Infliximab – Remicade	0
• Infliximab Biosimilar	8
• Secukinumab	25
• Ustekinumab – Stelara	0
• Ustekinumab Biosimilar	0

10 September 2026

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.